Literature DB >> 31469949

Therapy compliance in children with phenylketonuria younger than 5 years: A cohort study.

Dariusz Walkowiak1, Anna Bukowska-Posadzy2,3, Łukasz Kałużny2, Mariusz Ołtarzewski4, Rafał Staszewski1, Michał Musielak5, Jarosław Walkowiak2.   

Abstract

BACKGROUND: Phenylketonuria (PKU) is a metabolic disease. It is manifested by a complete or partial inability to convert phenylalanine (Phe) to tyrosine and leads to increased concentrations of Phe in the blood and in other tissues, including the brain, causing irreversible neurological damage if left untreated. Low-phenylalanine diet is a key component of classical PKU therapy.
OBJECTIVES: The objective of this study was to assess the effectiveness of classical phenylketonuria therapy and compliance with doctors' recommendations in the first 5 years of life.
MATERIAL AND METHODS: Data was collected from all diagnosed and treated patients (n = 57) born 1999-2010. Phenylalanine blood levels, the number of visits to a specialist outpatients' center, the number of blood tests, as well as socioeconomic status (SES) and parents' education level have been analyzed, and potential relationships have been assessed.
RESULTS: In the 1st year of life patients visited their doctors (odds ratio (OR) = 6.8267; 95% confidence interval (95% CI) = 2.827-16.5163; p < 0.0001) and had their blood collected (OR = 2.7875; 95% CI = 1.0467-7.4234; p < 0.0402) significantly more frequently than in the 2nd year. This tendency persisted into subsequent years. Similarly, in infancy they had statistically significantly lower odds of exceeding more than 40% of their Phe levels over therapeutic range than 1 year later (OR = 3.6078; 95% CI = 1.4859-8.7599; p < 0.0046). No PKU child had more than 70% of Phe levels over the therapeutic range in the 1st year of life, whereas 4 years later there were 18 such children. Phe levels were correlated with the number of visits to a specialist (ρ = 0.39) and the number of Phe blood tests with index of dietary control (ρ = -0.33). The effectiveness of therapy and compliance with the doctor's recommendations seem to depend neither on the level of education of the patient's parents nor on their SES.
CONCLUSIONS: Therapy effectiveness and patients' compliance in PKU is very good in infancy. However, both deteriorate in subsequent years. Moreover, they do not seem to depend on the family background.

Entities:  

Keywords:  compliance; diet; inborn errors of metabolism; phenylalanine; phenylketonuria

Mesh:

Substances:

Year:  2019        PMID: 31469949     DOI: 10.17219/acem/104536

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  3 in total

1.  The Impact of the COVID-19 Pandemic on the Perception of Health and Treatment-Related Issues among Patients with Phenylketonuria in Poland-The Results of a National Online Survey.

Authors:  Dariusz Walkowiak; Bożena Mikołuć; Renata Mozrzymas; Łukasz Kałużny; Bożena Didycz; Dorota Korycińska-Chaaban; Michał Patalan; Joanna Jagłowska; Agnieszka Chrobot; Ewa Starostecka; Joanna Zarębska; Jarosław Walkowiak
Journal:  Int J Environ Res Public Health       Date:  2021-06-13       Impact factor: 3.390

2.  The Impact of the First 2020 COVID-19 Lockdown on the Metabolic Control of Patients with Phenylketonuria.

Authors:  Dariusz Walkowiak; Bożena Mikołuć; Renata Mozrzymas; Łukasz Kałużny; Bożena Didycz; Joanna Jaglowska; Danuta Kurylak; Jarosław Walkowiak
Journal:  Nutrients       Date:  2021-06-12       Impact factor: 5.717

3.  Vitamin K Status in Adherent and Non-Adherent Patients with Phenylketonuria: A Cross-Sectional Study.

Authors:  Renata Mozrzymas; Dariusz Walkowiak; Sławomira Drzymała-Czyż; Patrycja Krzyżanowska-Jankowska; Monika Duś-Żuchowska; Łukasz Kałużny; Jarosław Walkowiak
Journal:  Nutrients       Date:  2020-06-14       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.